Fertility preservation of young patients with breast cancer

doi:10.3760/cma.j.issn.1673-422X.2014.02.010

Abstract

Abstract: It is an important problem to preserve fertility of young patients with breast cancer, which infects the life quality of patients. But fertility after treatment has an impact on longterm survival, so the appropriate pregnancy time should be chosen carefully. The fertility of breast canser patient suffers all kinds of damage after systemic therapy. At the present stage, the measures of fertility protection include application of gonadotropinreleasing hormone analogue, embryo cryopreservation, oocyte cryopreservation and ovarian tissue cryopreservation.

Key words: Breast neoplasms, Fertility

Duan Jiajun. Fertility preservation of young patients with breast cancer[J]. Journal of International Oncology, 2014, 41(2): 110-112.

References

［1］ Peate M, Meiser B, Cheah BC, et al. Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertilityrelated decision aid in young women with earlystage breast cancer［J］. Br J Cancer， 2012， 106 (6): 1053-1061. ［2］ Hill KA, Nadler T, Mandel R， et al. Experience of young women diagnosed with breast cancer who undergo fertility preservation consultation［J］. Clin Breast Cancer, 2012， 12(2): 127-132. ［3］ Corney RH, Swinglehurst AJ. Young childless women with breast cancer in the UK: a qualitative study of their fertilityrelated experiences, options, and the information given by health professionals［J］. Psychooncology， 2013， In press. ［4］ Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer［J］. N Engl J Med, 2010， 362(22): 2053-2065. ［5］ Kroman N, Jensen MB, Wohlfahrt J, et al. Pregnancy after treatment of breast cancer—a populationbased study on behalf of Danish Breast Cancer Cooperative Group［J］. Acta Oncol, 2008, 47(4): 545-549. ［6］ Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a metaanalysis of 14 studies［J］. Eur J Cancer, 2011， 47(1): 7483. ［7］ Largillier R, Savignoni A, Gligorov J, et al. Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged< 35 years: a CET(N)A Working Group analysis［J］. Cancer, 2009， 115(22): 5155-5165. ［8］ Sukumvanich P, Case LD, Van Zee K, et al. Incidence and time course of bleeding after longterm amenorrhea after breast cancer treatment: a prospective study［J］. Cancer, 2010， 116(3): 3102-3111. ［9］ Christinat A, Pagani O. Fertility after breast cancer［J］. Maturitas， 2012， 73(3): 191-196. ［10］ Christinat A, Di Lascio S, Pagani O. Hormonal therapies in young breast cancer patients: when, what and for how long? ［J］. J Thorac Dis， 2013， 5 Suppl 1: S36-46. ［11］ Oktay K, Türküoˇglu I, RodriguezWallberg KA, et al. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation［J］. Reprod Biomed Online， 2010， 20(6): 783-788. ［12］ Das M, Shehata F, Son WY, et al. Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy［J］. Hum Reprod， 2012， 27(8): 2509-2514. ［13］ Balber AE. Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine［J］. Stem Cell, 2011， 29(4): 570-575. ［14］ Pagani O, Partridge A, Korde L, et al. Pregnancy after breast cancer: if you wish, ma′am［J］. Breast Cancer Res Treat， 2011， 129(2): 309-317.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654.